Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HCN4 antisense RNA 1 (HCN4-AS1) is classified as a long non-coding RNA (lncRNA) that is transcribed antisense to the HCN4 gene. While antisense RNAs, especially lncRNAs, are widely recognized as regulators of gene expression at the levels of transcription, RNA processing, and translation, there is currently no published evidence that HCN4-AS1 itself acts as a bona fide therapeutic target, nor that it is involved in disease mechanisms, or modulated by specific drugs[6]. This makes it biologically distinct from the protein-coding HCN4 gene, which encodes a functional ion channel involved in cardiac pacemaker activity[1][2][5][8]. More research is needed to describe the specific roles, interactions, or clinical relevance of HCN4-AS1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HCN4 antisense RNA 1 (HCN4-AS1).